Citations

References

  1. Kuchekar BS, Badha AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. Pharmatimes 2003;35:7-9.
  2. Bahador, A., Lesan, S., & Kashi, N. (2012). Effect of xylitol on cariogenic and beneficial oral streptococci: a randomized, double-blind crossover trial. Iranian journal of microbiology4(2), 75–81.
  3. Scheinin, A., Mäkinen, K. K., Tammisalo, E., & Rekola, M. (1975). Turku sugar studies XVIII. Incidence of dental caries in relation to 1-year consumption of xylitol chewing gum. Acta odontologica Scandinavica33(5), 269–278. https://doi.org/10.3109/00016357509004632
  4. Wiebe, N., Padwal, R., Field, C., Marks, S., Jacobs, R., & Tonelli, M. (2011). A systematic review on the effect of sweeteners on glycemic response and clinically relevant outcomes. BMC medicine9, 123. https://doi.org/10.1186/1741-7015-9-123
  5. Papagianni, E. P., & Stevenson, C. W. (2019). Cannabinoid Regulation of Fear and Anxiety: an Update. Current psychiatry reports21(6), 38. https://doi.org/10.1007/s11920-019-1026-z
  6. Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente journal23, 18–041. https://doi.org/10.7812/TPP/18-041
  7. Bouaziz, J., Bar On, A., Seidman, D. S., & Soriano, D. (2017). The Clinical Significance of Endocannabinoids in Endometriosis Pain Management. Cannabis and cannabinoid research2(1), 72–80. https://doi.org/10.1089/can.2016.0035
  8. García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020). Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules10(11), 1575. https://doi.org/10.3390/biom10111575
  9. Prenderville, J. A., Kelly, Á. M., & Downer, E. J. (2015). The role of cannabinoids in adult neurogenesis. British journal of pharmacology172(16), 3950–3963. https://doi.org/10.1111/bph.13186
  10. Oláh A, Markovics A, Szabó-Papp J, Szabó PT, Stott C, Zouboulis CC, Bíró T. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp Dermatol. 2016 Sep;25(9):701-7. doi: 10.1111/exd.13042. Epub 2016 Jun 15. PMID: 27094344
  11. Trusler, A. R., Clark, A. K., Sivamani, R. K., & Shi, V. Y. (2017). The Endocannabinoid System and Its Role in Eczematous Dermatoses. Dermatitis : contact, atopic, occupational, drug28(1), 22–32. https://doi.org/10.1097/DER.0000000000000257
  12. Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65(6), 812–819. doi:10.1212/01.wnl.0000176753.45410.8b 
  13. Gonçalves, E. D., & Dutra, R. C. (2019). Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand? Drug Discovery Today. doi:10.1016/j.drudis.2019.05.023 
  14. Peyravian, N., Deo, S., Daunert, S., & Jimenez, J. J. (2020). Cannabidiol as a Novel Therapeutic for Immune Modulation. ImmunoTargets and therapy9, 131–140. https://doi.org/10.2147/ITT.S263690
  15. Klein, M., Gonçalves Salum, F., Cherubini, K., & Zancanaro de Figueiredo, M. A. (2020). Cannabidiol As A Novel Therapeutic Strategy For Oral Inflammatory Diseases: A Review Of Current Knowledge And Future Perspectives. Alternative therapies in health and medicine, 26(S1), 12–16.